Disclosed herein, inter alia, are trioxolane compounds and methods of using the same for treatment and detection of diseases.

Disclosed herein, inter alia, are trioxolane compounds and methods of using the same for treatment and detection of diseases.

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to the prevention and treatment of Alzheimer's disease

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to the prevention and treatment of Alzheimer's disease

The present disclosure provides improved methods of performing ozonolysis on alkenes comprising non-reductive quenching of ozonide intermediates using Bronsted bases to yield aldehyde, ketone and/or carboxylic acid products.

Disclosed herein, inter alia, are prodrug compositions and methods of using the same for treatment and detection of disease. Specifically, disclosed herein is a compound of formula (I) having spiro-fused 1,2,4-trioxolane and piperidine rings, namely, 1,2,4-trioxa-8-azaspiro[4.5] decane. Also disclosed is a pharmaceutical composition containing the compound and a pharmaceutically acceptable carrier.

##STR00001##

Disclosed herein, inter alia, are prodrug compositions and methods of using the same for treatment and detection of disease. Specifically, disclosed herein is a compound of formula (I) having spiro-fused 1,2,4-trioxolane and piperidine rings, namely, 1,2,4-trioxa-8-azaspiro[4.5] decane. Also disclosed is a pharmaceutical composition containing the compound and a pharmaceutically acceptable carrier.

##STR00001##

A method for producing jet range hydrocarbons may include reacting at least a portion a fatty acid stream comprising C18:1 free fatty acid with ozone in an ozonolysis unit to form at least a C18:1 ozonide intermediate; introducing the C18:1 ozonide intermediate into a reactor, wherein at least a portion of the C18:1 ozonide intermediate is reacted with a reductive agent to produce oxidized products comprising azelaic acid and nonanoic acid; and introducing the oxidized products into a hydrotreating unit, wherein at least a portion of the oxidized products is hydrotreated to produce a paraffin product comprising nonane.

A method for producing jet range hydrocarbons may include reacting at least a portion a fatty acid stream comprising C18:1 free fatty acid with ozone in an ozonolysis unit to form at least a C18:1 ozonide intermediate; introducing the C18:1 ozonide intermediate into a reactor, wherein at least a portion of the C18:1 ozonide intermediate is reacted with a reductive agent to produce oxidized products comprising azelaic acid and nonanoic acid; and introducing the oxidized products into a hydrotreating unit, wherein at least a portion of the oxidized products is hydrotreated to produce a paraffin product comprising nonane.

The present disclosure provides improved methods of performing ozonolysis on alkenes comprising non-reductive quenching of ozonide intermediates using Bronsted bases to yield aldehyde, ketone and/or carboxylic acid products.